Cara Therapeutics

New York, United States Founded: 2004 • Age: 22 yrs Listed
Developer of therapeutics for pain relief and inflammatory diseases

About Cara Therapeutics

Cara Therapeutics is a publicly listed company based in New York (United States) founded in 2004. Developer of therapeutics for pain relief and inflammatory diseases. Cara Therapeutics has raised $51 million across 5 funding rounds from investors including MVM Partners, Rho Capital Partners and Alta Partners. The company has 79 employees. Its chief executive, as recorded, is Christopher Posner. Cara Therapeutics offers products and services including IPF Therapy and Liver Cancer Treatment. Its focus areas include Life Sciences, Neurology, Drugs and Pain. Its competitors include Avidity Biosciences, Flexion Therapeutics and Sutro Biopharma; 3 of its 3 listed competitors have raised funding.

Company details

Cara Therapeutics is developing cannabinoid and opioid receptor targeting therapeutics for pain relief and inflammatory diseases. Its proprietary technology DimerScreen identifies molecular structures that interact with the G-Protein-Coupled Receptors (GPCRS). Its lead candidate, CR845, is a peripheral kappa-opioid receptor agonist and is in Phase III trials for acute postoperative pain and pruritis. The company is also developing cannabinoid receptor agonists for pain relief.

  • Headquarters New York, United States
  • Employees 79
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website caratherapeutics.com
  • Social LinkedIn X
Key Metrics
  • Annual Revenue
    $4.33 M (USD)
    943
    as on Dec 31, 2024
  • Net Profit
    -$70.87 M (USD)
    40
    as on Dec 31, 2024
  • EBITDA
    -$58.38 M (USD)
    52
    as on Dec 31, 2024
  • Total Equity Funding
    $51M (USD)

    in 5 rounds

  • Latest Funding Round
    $100K (USD), Post-IPO

    Dec 2014

  • Investors
  • Employee Count
    79

Products & Services of Cara Therapeutics

Cara Therapeutics offers a comprehensive portfolio of products and services, including IPF Therapy and Liver Cancer Treatment.

IPF Therapy
Clinical Trial Drug

Treatment for idiopathic pulmonary fibrosis through research trials.

Liver Cancer Treatment
Oncology Drug

Therapy targeting liver cancer in advanced stages.

Funding Insights of Cara Therapeutics

Cara Therapeutics has successfully raised a total of $51M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $100 thousand completed in December 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $51M
  • Total Rounds 5
  • Last Round Post-IPO β€” $100,003
  • First Round $4.7M

    (Dec 2005)

  • Investors Count 8

All 5 funding rounds of Cara Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2014$100,003Post-IPO––
–
Jul 2010$15MSeries D–Rho Capital Partners, SWIP
Jul 2008$12.3MSeries C––
Nov 2006$19MSeries C––
Dec 2005$4.7MSeries B––
Valuation history

8 investors in total: 8 institutional.

Investors in Cara Therapeutics

Cara Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include MVM Partners, Rho Capital Partners and Alta Partners.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Early-stage tech startups are invested in by Rho Capital Partners.
rho.comNew York, United States
Venture capital firm focused on healthcare companies
altapartners.comJackson, United States
Venture capital services for biotech, IT, and innovative sectors in Connecticut.
ctinnovations.com
abvlp.com
dpbioventures.com
Private equity investments in healthcare companies are managed.
1997mvm.comLondon, United Kingdom
Esperante is focused on innovative life science investments.
esperante.comHoofddorp, Netherlands
Offers investment management services focused on portfolio construction and risk assessment.
1996swip.comLondon, United Kingdom
Premium access

Investor details for Cara Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Cara Therapeutics

25 people are tracked at Cara Therapeutics (17 in leadership, 4 in board & advisors, 4 in team); the tracked headcount is 79.

NameRoleGroup
Christopher Posner
CEOLeadership
Frédérique Menzaghi
Chief Scientific Officer, SVP Research & DevelopmentLeadership
Scott Terrillion
General Counsel, Secretary & Chief Compliance OfficerLeadership
Rene Barron
Executive Director, HRLeadership
Ryan Maynard
Chief Financial OfficerLeadership
Zachary Piracha
Associate Director, Drug Safety PharmacovigilanceLeadership
Jo Goncalves
Chief Medical OfficerLeadership
Nilam Shah
Vice President, Clinical Research And DevelopmentLeadership
Diane Roth
Associate Director Clinical Project ManagementLeadership
Alia Jebara
Senior Medical DirectorLeadership
Michele Paz
Director Of FinanceLeadership
Rick Makara
Vice President, Head Of Accounting And ControllerLeadership
Stephen O’Connor
Vice President CMC Technical OperationsLeadership
Tennador Sanderson
Sr. Director, Clinical Research & DevelopmentLeadership
Kristine Nograles
Vice President, Clinical DevelopmentLeadership
Andrew Albright
Executive Director, Alliance Management And Chief Of StaffLeadership
Ralph Vaccaro
Executive Director, Information TechnologyLeadership
Jeffrey L. Ives
DirectorBoard & advisors
Lisa von Moltke
DirectorBoard & advisors
Martin Vogelbaum
ChairmanBoard & advisors

5 more people are available in the full profile.

Premium access

Complete people profiles for Cara Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Cara Therapeutics

4 dated milestones of Cara Therapeutics across 11 years, from founding to its latest funding, stage changes and deals.

  1. Founded Cara Therapeutics is founded.
  2. Funding First funding round of $4.7M.
  3. Funding Latest funding round, Post-IPO, of $100K.
  4. IPO Lists on the stock exchange (IPO).

Competitors of Cara Therapeutics

Cara Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Flexion Therapeutics and Sutro Biopharma.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
aviditybiosciences.com2012San Diego, United States$142.54M253
Antibody-siRNA complexes are developed for cancer treatment.
flexiontherapeutics.com2007Woburn, United States$62M692
Developer of therapies for the treatment of musculoskeletal disorders
sutrobio.com2003United States$171.85M235
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
Premium access

Detailed competitors of Cara Therapeutics

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Pain Management

3 companies that operate in the same segment as Cara Therapeutics (Pain Management) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Developer of therapies for the treatment of musculoskeletal disorders
2007Woburn, Massachusetts, United StatesUSD 62 MUSD 85.55 M692
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed.
2007Philadelphia, Pennsylvania, United StatesUSD 203 MUSD 3.13 M35
Therapeutics for migraine treatment are developed using nasal delivery.
2016San Francisco, California, United StatesUSD 74.13 M24
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Cara Therapeutics

Premium access

Complete news archive for Cara Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Cara Therapeutics

Cara Therapeutics was founded in 2004 and raised its 1st funding round 1 year after it was founded.

Cara Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.

Christopher Posner is the CEO of Cara Therapeutics, as recorded in our data.

Cara Therapeutics is a funded company, having raised a total of $51M across 5 funding rounds to date. The company's 1st funding round was a Series B of $4.7M, raised on Dec 2005.

Cara Therapeutics has 79 employees.

Annual revenue of Cara Therapeutics is $4.33M as on Dec 31, 2024.

Cara Therapeutics is developing cannabinoid and opioid receptor targeting therapeutics for pain relief and inflammatory diseases. Its proprietary technology DimerScreen identifies molecular structures that interact with the G-Protein-Coupled Receptors (GPCRS). Its lead candidate, CR845, is a peripheral kappa-opioid receptor agonist and is in Phase III trials for acute postoperative pain and pruritis. The company is also developing cannabinoid receptor agonists for pain relief.

Cara Therapeutics's top competitors include Sutro Biopharma, Flexion Therapeutics and Avidity Biosciences.

Cara Therapeutics offers IPF Therapy and Liver Cancer Treatment.

Cara Therapeutics has 8 investors. Key investors include MVM Partners, Rho Capital Partners, Alta Partners, Connecticut Innovations, and SWIP.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available